FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer.

CONCLUSION: Collectively, these findings suggest that while FGFR1 amplification confers broad resistance to ER, PI3K, and CDK4/6 inhibitors, TORC1 inhibitors might have a unique therapeutic role in the treatment of patients with ER+/FGFR1+ MBC.
PMID: 31371343 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 31, 2019 Category: Cancer & Oncology Authors: Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A Tags: Clin Cancer Res Source Type: research